Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Asahi Kasei Therapeutics Doses First Patient in AIC468 PIIa Trial
Asahi Kasei said on October 9 that its US subsidiary Asahi Kasei Therapeutics has dosed the first patient in a PIIa trial of AIC468, an investigational antiviral antisense oligonucleotide (ASO) for BK virus infection in kidney transplant recipients. The randomized,…
To read the full story
Related Article
- Asahi Kasei Rebrands Pharma Units under Common Global Name
September 30, 2026
- Asahi Kasei Closes Aicuris Buy, Eyes US$500 Million Sales by 2030
April 21, 2026
BUSINESS
- DNP, CMIC, NEXEL Form JV to Take iPSC-Based Drug Testing Global
October 13, 2026
- Asahi Kasei Therapeutics Doses First Patient in AIC468 PIIa Trial
October 13, 2026
- Kissei Group Firm Hit by Cyberattack, Personal Data at Risk
October 13, 2026
- Toho Drops PHC Buyout Bid, Still Exploring Growth Options
October 13, 2026
- Sanwa Kagaku on Track to Resume Kumamoto Production in October
October 13, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…